Apex Biotechnology Corp.(TW:1733)
NT$28.55-0.20 (-1.04%)
TW:1733
Apex Biotechnology Corp. financials statements
NT$28.55
At close:-0.20 (-1.04%)
Apex Biotechnology Corp. (1733) Ratios
Apex Biotechnology Corp. Ratios
TW:1733's free cash flow for Q2 2026 was NT$161.49M. For the 2026 fiscal year, TW:1733's free cash flow was decreased by NT$-2.79M and operating cash flow was NT$164.28M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.87 | 3.44 | 3.93 | 2.90 | 2.24 |
| Quick Ratio | 2.57 | 2.05 | 1.98 | 1.60 | 1.44 |
| Cash Ratio | 1.31 | 1.11 | 1.00 | 0.58 | 0.71 |
| Solvency Ratio | 0.41 | 0.32 | 0.38 | 0.40 | 0.32 |
| Operating Cash Flow Ratio | 0.38 | 0.69 | 0.60 | 0.05 | 0.23 |
| Short-Term Operating Cash Flow Coverage | 4.19 | 7.61 | 4.01 | 0.24 | 0.86 |
| Net Current Asset Value | NT$ 1.13B | NT$ 1.05B | NT$ 1.01B | NT$ 957.67M | NT$ 842.94M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.07 | 0.08 | 0.10 | 0.13 |
| Debt-to-Equity Ratio | 0.08 | 0.09 | 0.10 | 0.13 | 0.20 |
| Debt-to-Capital Ratio | 0.07 | 0.08 | 0.09 | 0.12 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.29 | 1.33 | 1.28 | 1.38 | 1.52 |
| Debt Service Coverage Ratio | 4.11 | 4.20 | 3.17 | 2.37 | 1.39 |
| Interest Coverage Ratio | 41.54 | 35.29 | 32.30 | 37.97 | 15.48 |
| Debt to Market Cap | 0.01 | 0.01 | 0.01 | 0.04 | 0.08 |
| Interest Debt Per Share | 1.52 | 1.69 | 1.86 | 2.49 | 3.57 |
| Net Debt to EBITDA | -2.07 | -1.65 | -0.91 | -0.29 | -0.73 |
| Profitability Margins | |||||
| Gross Profit Margin | 27.70% | 28.15% | 31.68% | 25.70% | 26.81% |
| EBIT Margin | 7.24% | 8.46% | 8.67% | 7.87% | 9.26% |
| EBITDA Margin | 10.37% | 11.96% | 13.19% | 13.33% | 13.59% |
| Operating Profit Margin | 7.24% | 6.94% | 8.45% | 9.13% | 9.10% |
| Pretax Profit Margin | 9.76% | 8.27% | 8.41% | 8.89% | 8.68% |
| Net Profit Margin | 8.38% | 6.91% | 6.91% | 8.10% | 9.49% |
| Continuous Operations Profit Margin | 8.38% | 6.92% | 6.90% | 8.09% | 9.49% |
| Net Income Per EBT | 85.86% | 83.59% | 82.14% | 91.09% | 109.35% |
| EBT Per EBIT | 134.94% | 119.16% | 99.47% | 97.37% | 95.34% |
| Return on Assets (ROA) | 6.75% | 5.29% | 5.04% | 7.23% | 7.57% |
| Return on Equity (ROE) | 8.72% | 7.02% | 6.45% | 10.00% | 11.54% |
| Return on Capital Employed (ROCE) | 7.09% | 6.62% | 7.41% | 10.54% | 10.29% |
| Return on Invested Capital (ROIC) | 5.95% | 5.39% | 5.88% | 9.02% | 9.24% |
| Return on Tangible Assets | 6.85% | 5.38% | 5.14% | 7.43% | 7.89% |
| Earnings Yield | 5.35% | 4.24% | 2.88% | 7.12% | 7.80% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.35 | 5.22 | 5.70 | 4.52 | 4.36 |
| Payables Turnover | 7.30 | 6.80 | 8.89 | 7.36 | 5.47 |
| Inventory Turnover | 2.50 | 2.01 | 1.53 | 2.26 | 2.48 |
| Fixed Asset Turnover | 2.97 | 2.64 | 2.32 | 2.91 | 2.67 |
| Asset Turnover | 0.81 | 0.77 | 0.73 | 0.89 | 0.80 |
| Working Capital Turnover Ratio | 1.62 | 1.62 | 1.52 | 2.18 | 2.40 |
| Cash Conversion Cycle | 179.87 | 197.89 | 261.26 | 193.07 | 163.97 |
| Days of Sales Outstanding | 84.00 | 69.90 | 64.03 | 80.82 | 83.62 |
| Days of Inventory Outstanding | 145.84 | 181.69 | 238.27 | 161.83 | 147.06 |
| Days of Payables Outstanding | 49.97 | 53.70 | 41.04 | 49.57 | 66.71 |
| Operating Cycle | 229.84 | 251.59 | 302.30 | 242.65 | 230.68 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.64 | 3.28 | 2.31 | 0.27 | 1.80 |
| Free Cash Flow Per Share | 1.49 | 2.98 | 2.06 | -0.14 | 1.54 |
| Dividend Paid and CapEx Coverage Ratio | 1.21 | 2.35 | 1.40 | 0.16 | 1.33 |
| Capital Expenditure Coverage Ratio | 10.76 | 11.09 | 9.22 | 0.66 | 6.87 |
| Operating Cash Flow Coverage Ratio | 1.10 | 1.98 | 1.27 | 0.11 | 0.52 |
| Operating Cash Flow to Sales Ratio | 0.08 | 0.18 | 0.14 | 0.01 | 0.08 |
| Free Cash Flow Yield | 4.89% | 9.91% | 5.11% | -0.53% | 5.93% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 18.68 | 23.52 | 34.74 | 14.04 | 12.81 |
| Price-to-Sales (P/S) Ratio | 1.57 | 1.63 | 2.40 | 1.14 | 1.22 |
| Price-to-Book (P/B) Ratio | 1.63 | 1.65 | 2.24 | 1.41 | 1.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 20.46 | 10.09 | 19.58 | -187.99 | 16.87 |
| Price-to-Operating Cash Flow Ratio | 18.56 | 9.18 | 17.46 | 95.95 | 14.42 |
| Price-to-Earnings Growth (PEG) Ratio | 0.68 | 2.27 | -0.96 | -1.36 | 0.11 |
| Enterprise Value Multiple | 13.03 | 11.96 | 17.29 | 8.25 | 8.22 |
| Enterprise Value | 2.63B | 2.65B | 3.82B | 2.47B | 2.38B |
| EV to EBITDA | 13.03 | 11.96 | 17.29 | 8.25 | 8.22 |
| EV to Sales | 1.35 | 1.43 | 2.28 | 1.10 | 1.12 |
| EV to Free Cash Flow | 17.65 | 8.86 | 18.60 | -181.53 | 15.49 |
| EV to Operating Cash Flow | 16.01 | 8.06 | 16.59 | 92.65 | 13.24 |
| Tangible Book Value Per Share | 18.34 | 17.81 | 17.56 | 17.50 | 16.52 |
| Shareholders’ Equity Per Share | 18.69 | 18.20 | 18.00 | 18.18 | 17.57 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.14 | 0.16 | 0.18 | 0.09 | -0.09 |
| Revenue Per Share | 19.44 | 18.48 | 16.80 | 22.45 | 21.37 |
| Net Income Per Share | 1.63 | 1.28 | 1.16 | 1.82 | 2.03 |
| Tax Burden | 0.86 | 0.84 | 0.82 | 0.91 | 1.09 |
| Interest Burden | 1.35 | 0.98 | 0.97 | 1.13 | 0.94 |
| Research & Development to Revenue | 0.08 | 0.09 | 0.10 | 0.07 | 0.07 |
| SG&A to Revenue | 0.12 | 0.12 | 0.13 | 0.10 | 0.10 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.01 | 2.15 | 1.63 | 0.13 | 0.97 |
Currency in TWD
